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How was it discovered?
Rapamycin was discovered on
Easter Island in a natural product
screen for anti-fungicides and is
produced by the soil bacteria,
Streptomyces hygroscopicus. 
The Target of Rapamycin (TOR)
was found in the yeast,
Saccharomyces cerevisae, in a
screen for mutants resistant 
to the cytostatic effects of the
anti-mycotic. Two isoforms of 
the yeast protein were identified,
TOR1 and 2. TOR orthologues
have been found in all eukaryotes
examined to date.
What does it look like? It is 
a protein of about 300 kDa,
containing multiple subdomains
whose sequence and positioning
have been conserved throughout
evolution. It contains a
phosphatidylinositide (PI) 3-kinase
like catalytic domain, which is
closely related to the catalytic
domains of the DNA damage
repair protein kinases ATM, ATR
and DNA-dependent protein
kinase. The TOR catalytic domain
has protein kinase activity that is
important for biological function.
The FRB domain, adjacent to the
catalytic domain, is the region
where rapamycin binds, together
with the immunophilin FKBP12, to
inhibit TOR function, and has
recently been implicated in the
binding of phosphatidic acid. Two
additional regions, the HEAT
repeats and FAT domain, may
provide docking sites for other
proteins, but as yet have no
docking partners.
What does it do? Work in yeast
and metazoans has shown that
TOR plays a major role in
regulating cell growth through 
the control of protein synthesis. 
In addition, evidence is
accumulating that TOR also
regulates transcription of certain
genes and controls protein
degradation through autophagy. A
common feature relating to TOR
function in lower and higher
eukaryotes is its presence in
nutrient sensing pathways, where
it controls the rate of anabolic and
catabolic processes as a function
of nutrient availability. The
situation is more complicated in
metazoans, in that TOR acts as a
junction for both nutrient and
mitogenic signals, relaying this
information to downstream
targets.
How is it regulated? Studies
regarding TOR regulation have
mainly focused on the mammalian
form of the enzyme (mTOR).
Although some reports have
provided evidence that mTOR is
downstream of PI 3-kinase and
activated by phosphorylation it is
unclear what role phosphorylation
plays in its activation, as
phosphorylation site mutants 
have not been shown to affect
mTOR signaling. More recent
studies have shown that
mTOR-specific activity can be
modulated in the cell by levels of
small molecules such as
branched-chain amino acids, 
ATP and phosphatidic acid. These
molecules may serve as the link
between mitogen pathways and
nutrient signals.
Is it a potential therapeutic
target? Yes! One of the earliest
observations indicating the
therapeutic importance of mTOR
involved the immunosuppressive
effects of its inhibitor, rapamycin.
Indeed, a form of rapamycin
(Rapammune®) is on the market
for use in organ transplantation.
Recently, Phase I clinical trials
were completed in which another
form of rapamycin (CCI-779) was
tested in patients with solid
tumors. The results of the trial
indicated efficacy at sub-toxic
doses and suggested that some
tumors may be more sensitive to
inhibition of the mTOR pathway
than others. Currently,
homologues of rapamycin are in
broad-based efficacy trials to
determine if treatment of other
pathological conditions could
benefit from this remarkable
natural product.
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Figure 1. Schematic of mTOR with known regulators.
The individual subdomains of mTOR are shown on the figure along with PKB phospho-
rylation sites (T2446 and S2448) and the autophosphorylation site S2481. Arrows show
the target subdomains of regulatory small molecules, with the exception of L-leucine
whose mechanism of regulation is not known. Domains shown are: catalytic (yellow),
FKBP12/rapamycin binding (orange), FAT (green) and HEAT (red).
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